June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Corneal Opacity in The United States: An Epidemiological Study from the IRIS Registry
Author Affiliations & Notes
  • Erdem Yuksel
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Nathan Eli Hall
    Schepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Rohan Bir Singh
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Jia Yin
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Tobias Elze
    Schepens Eye Research Institute of Mass Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Lucia Sobrin
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Joan W Miller
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Alice Lorch
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Reza Dana
    Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Erdem Yuksel, None; Nathan Hall, None; Rohan Singh, None; Jia Yin, None; Tobias Elze, None; Lucia Sobrin, None; Joan Miller, Genentech/Roche (C), Genentech/Roche (R), KalVista Therapeutics (C), Lowy Medical Research Institute (F), ONL Therapeutics (C), ONL Therapeutics (P), ONL Therapeutics (I), ONL Therapeutics (R), Sunovion (C), Valeant Pharmaceuticals/MEE (P), Valeant Pharmaceuticals/MEE (R); Alice Lorch, None; Reza Dana, None
  • Footnotes
    Support  Turkish Science Fellowships and Grant Programmes of The Scientific and Technological Research Council of Turkey (EY), NIH K12 EY016335 (JY), NIH R21 EY030142, R21 EY030631, R01 EY030575, K99 EY028631, P30 EY003790; BrightFocus Foundation; Grimshaw-Gudewicz Foundation; Research to Prevent Blindness; Lions Foundation; Alice Adler Fellowship (TE), NIH R01 EY012963; NIH R21 EY029387; DoD VR170189 (RD).
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3995. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erdem Yuksel, Nathan Eli Hall, Rohan Bir Singh, Jia Yin, Tobias Elze, Lucia Sobrin, Joan W Miller, Alice Lorch, Reza Dana; Corneal Opacity in The United States: An Epidemiological Study from the IRIS Registry. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3995.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Data on the prevalence and incidence of corneal opacity (CO) are sparse in the United States. In this study, we performed a retrospective analysis of the electronic health record data to determine the epidemiology and associated demographic and clinical characteristics of CO using the American Academy of Ophthalmology’s IRIS® Registry (Intelligent Research in Sight).

Methods : The IRIS registry contains data of 45,261,877 individual patients with recorded eye clinic visits from January 1, 2013 to December 31, 2017. CO was identified by using International Classification of Disease (ICD) codes (ICD-9, and -10) of “371” (corneal scar) and “H17” (corneal opacity). The recorded demographic parameters included age and sex, and the clinical data included laterality, associated ICD codes, and best-corrected visual acuity (BCVA) before, during, and after onset of CO.

Results : A total of 3,357,219 patients were identified with CO in one or both eyes. Among those patients, 111,809 patients had a new diagnosis of CO in 2017. The mean age of the cohort was 64.2±17.2 years and 56% of patients were female (p<0.001). In those with CO, 90.1% had unilateral involvement and 9.9% had bilateral involvement (p<0.001). The prevalence of CO increased with age and was highest among those over 65 (p<0.001). The most common corneal diagnoses associated with CO were corneal dystrophies, keratoconjunctivitis, keratitis, corneal degenerations and corneal injuries. The mean BCVA during and after onset of CO was 20/80 (p<0.001), and 20/41 respectively (p<0.001), compared to 20/36 before onset.

Conclusions : Using the IRIS Registry, we identified 3,357,219 patients diagnosed with corneal opacity. CO is mostly unilateral and leads to a decrease in the visual acuity of those affected.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×